Javier
Corral De La Calle
Profesor Titular de Universidad Vinculado H.U.M.M.
Vanessa
Roldan Schilling
Catedraticos de Universidad Vinculados H.V.Arrixaca
Publicaciones en las que colabora con Vanessa Roldan Schilling (43)
2023
-
Factor XI in Carriers of Antiphospholipid Antibodies: Elevated Levels Associated with Symptomatic Thrombotic Cases, While Low Levels Linked to Asymptomatic Cases
International Journal of Molecular Sciences, Vol. 24, Núm. 22
2021
-
Anticoagulant therapy in patients with congenital FXI deficiency
Blood Advances, Vol. 5, Núm. 20, pp. 4083-4086
2020
-
ALG12-CDG: An unusual patient without intellectual disability and facial dysmorphism, and with a novel variant
Molecular Genetics and Genomic Medicine, Vol. 8, Núm. 8
-
Factor XII in PMM2-CDG patients: Role of N-glycosylation in the secretion and function of the first element of the contact pathway
Orphanet Journal of Rare Diseases, Vol. 15, Núm. 1
2018
-
Assessment of two contact activation reagents for the diagnosis of congenital factor XI deficiency
Thrombosis Research, Vol. 163, pp. 64-70
2017
-
High incidence of FXI deficiency in a Spanish town caused by 11 different mutations and the first duplication of F11: Results from the Yecla study
Haemophilia, Vol. 23, Núm. 6, pp. e488-e496
2016
-
Genotype-guided therapy improves initial acenocoumarol dosing: Results from a prospective randomised study
Thrombosis and Haemostasis, Vol. 115, Núm. 1, pp. 117-125
-
Hypoglycosylation is a common finding in antithrombin deficiency in the absence of a SERPINC1 gene defect
Journal of Thrombosis and Haemostasis, Vol. 14, Núm. 8, pp. 1549-1560
2015
-
A new method to quantify β-antithrombin glycoform in plasma reveals increased levels during the acute stroke event
Thrombosis Research, Vol. 136, Núm. 3, pp. 634-641
2014
-
Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment
Pharmacogenomics, Vol. 15, Núm. 7, pp. 987-996
2013
-
Association of the thrombomodulin gene c.1418c7gt;t polymorphism with thrombomodulin levels and with venous thrombosis risk
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 33, Núm. 6, pp. 1435-1440
-
Creating a genotype-based dosing algorithm for acenocoumarol steady dose
Thrombosis and Haemostasis, Vol. 109, Núm. 1, pp. 146-153
-
Novel Associations of VKORC1 Variants with Higher Acenocoumarol Requirements
PLoS ONE, Vol. 8, Núm. 5
2012
-
miR-133a regulates Vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the Vitamin K cycle
Molecular Medicine, Vol. 18, Núm. 11, pp. 1466-1472
2011
-
Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome
Journal of Thrombosis and Haemostasis, Vol. 9, Núm. 10, pp. 1985-1992
2010
-
Deep venous thrombosis or pulmonary embolism and factor V leiden: Enigma or paradox
Haematologica
-
Influence of the F12-4 C>T polymorphism on hemostatic tests
Blood Coagulation and Fibrinolysis, Vol. 21, Núm. 7, pp. 632-639
-
Pharmacogenetics of acenocoumarol in patients with extreme dose requirements
Journal of Thrombosis and Haemostasis, Vol. 8, Núm. 5, pp. 1012-1017
-
Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders
Annals of Hematology, Vol. 89, Núm. 11, pp. 1147-1154
-
Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction
Thrombosis and Haemostasis